Collection of Data and Samples From Healthy Donors for Use in Translational Research
NCT00090662 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 150
Last updated 2026-05-22
Summary
Increased numbers of white blood cells called eosinophils can cause disease. To investigate this disease, researchers need blood, urine, sputum, stool, cerebrospinal fluid, skin and/or bone marrow samples to compare to samples from patients with this problem. Some of the samples will be used for genetic testing or future research.
This study will last for about 10 years and will include a maximum of 50 paid volunteers ages 18 to 65.
Conditions
- Healthy Volunteer
Sponsors & Collaborators
-
National Institute of Allergy and Infectious Diseases (NIAID)
lead NIH
Principal Investigators
-
Amy D Klion, M.D. · National Institute of Allergy and Infectious Diseases (NIAID)
Eligibility
- Min Age
- 18 Years
- Max Age
- 85 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2004-12-09
Countries
- United States
Study Locations
More Related Trials
-
Studies of the Immune Response in Normal Subjects and Patients With Disorders of the Immune System
NCT00001158 ·Status: COMPLETED
-
Collection of Peripheral Blood Mononuclear Cells (PBMCs) From Healthy People for the Expansion of T Cells for Adoptive Cell Therapy
NCT02821806 ·Status: RECRUITING
-
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
NCT00177268 ·Status: RECRUITING
-
Collection of Immunology Specimens From Patients With Cancer or Blood Disorders, and Healthy Volunteers
NCT03207854 ·Status: RECRUITING
-
Dendritic Cells (DC) Vaccine for Metastatic Melanoma
NCT01042366 ·Status: TERMINATED ·Phase: PHASE2
-
Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer
NCT00823524 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Long-term Follow-Up Study Following Treatment With Fate Therapeutics' Engineered Cellular Immunotherapy
NCT04093622 ·Status: TERMINATED
-
Sargramostim for Myeloid Dendritic Cell Deficiency
NCT03063242 ·Status: TERMINATED ·Phase: PHASE2
-
Analysis of Dendritic Phenotype and Function of Patients Receiving VEGF-Trap on VGFT-ST-0202
NCT00896662 ·Status: COMPLETED
-
Vaccination With Dendritic Cell/Tumor Fusions With Autologous Stem Cell Transplants in Patients With Multiple Myeloma
NCT00458653 ·Status: COMPLETED ·Phase: PHASE1
-
Immune-Related Adverse Events and Associated Biomarkers in Patients Receiving Cancer Immunotherapy
NCT06089967 ·Status: COMPLETED
-
Collection of Research Data and Samples From Patients Who Experience Immunotherapy Side Effects
NCT04242095 ·Status: RECRUITING
-
Immune Cell Response to Stimuli
NCT00397280 ·Status: RECRUITING
-
Immunobiology Blood and Tissue Collection of Upper Aerodigestive Malignancies
NCT05995821 ·Status: RECRUITING
-
In Vitro Studies of Immunological and Stem Cell Function in Peripheral Blood Mononuclear Cells in Patients
NCT00001336 ·Status: COMPLETED
-
Immunization Against Tumor Cells in Sezary Syndrome
NCT00099593 ·Status: COMPLETED ·Phase: PHASE2
-
Identification of B Regulatory Cells by Flow Cytometry
NCT06876506 ·Status: NOT_YET_RECRUITING
-
Gene Therapy Follow up Protocol for Subjects Previously Enrolled in NCI Center for Immuno-Oncology Studies
NCT04266093 ·Status: ENROLLING_BY_INVITATION
-
Vaccine Therapy in Treating Patients With Non-Small Cell Lung Cancer
NCT00023985 ·Status: COMPLETED ·Phase: PHASE1
-
Multi Tumor-Associated Antigen-Specific T Lymphocytes to Treat Patients With High Risk Solid Tumors
NCT05238792 ·Status: RECRUITING ·Phase: PHASE1
-
Prospective Study of White Blood Cells
NCT04838171 ·Status: RECRUITING
-
T-helper 2 (Th2) Cytokine Responses in Overweight/Obese Subjects
NCT02085759 ·Status: COMPLETED
-
Biological Therapy in Treating Patients With Advanced Cancer
NCT00005956 ·Status: COMPLETED ·Phase: NA
-
Efficacy of Dendritic Cell Therapy for Myeloid Leukemia and Myeloma
NCT00965224 ·Status: COMPLETED ·Phase: PHASE2
-
Vaccine Therapy in Treating Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer
NCT00103116 ·Status: COMPLETED ·Phase: PHASE2